CRISPR THERAPEUTICS AG (CRSP) Stock Analyst Earnings Estimates
NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.2M -99.87% | 371.206M 30,833.83% | 37.314M -89.95% | 60.732M 62.76% | 175.96M 189.73% | 405.27M 130.32% | 1.64B 304.67% | 2.974B 81.34% | 5.734B 92.80% | 1.508B -73.70% | 1.836B 21.75% | |
| EBITDA YoY % growth | -649M -265.77% | -202.701M 68.77% | -447.307M -120.67% | -464.526M -3.85% | -429.853M 7.46% | -232.56M 45.90% | 33.66M 114.47% | 379.44M 1,027.27% | 728.28M 91.94% | 1.214B 66.69% | 1.693B 39.46% | |
| EBIT YoY % growth | -673.2M -280.24% | -222.538M 66.94% | -466.566M -109.66% | -496.05M -6.32% | -394.898M 20.39% | -246.207M 37.65% | 238.28M 196.78% | 219.59M -7.84% | 409.36M 86.42% | 583.47M 42.53% | 725.61M 24.36% | |
| Operating Margin | -56,100.00% | -59.95% | -1,250.38% | -816.79% | -224.42% | -60.75% | 14.53% | 7.38% | 7.14% | 38.69% | 39.52% | |
| EPS YoY % growth | -8.37 -289.37% | -1.96 76.58% | -4.37 -122.96% | -4.98 -13.85% | -4.14 16.70% | -1.97 52.37% | 3.25 264.42% | 10.47 222.46% | 25.21 140.88% | 6.49 -74.25% | 8.26 27.25% |
All data in USD
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.28 10.24% | -1.28 14.36% | -1.24 -23.22% | -1.20 -172.28% | -0.92 28.08% | -0.84 34.05% | -0.40 68.04% | -0.21 82.55% |
| Revenue Q2Q % growth | 8.26M 1,538.89% | 12.48M 2,313.93% | 16.814M 2,693.02% | 21.53M -39.68% | 70.584M 754.53% | 86.19M 590.63% | 107.61M 540.00% | 126.99M 489.83% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -132.648M 5.65% | -132.143M 12.64% | -124.402M -12.96% | -125.544M -94.38% | -100.164M 24.49% | -86.7M 34.39% | -69.564M 44.08% | -52.836M 57.91% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | -0.44 -140.00% | -1.19 | 0.75 | 63.08% |
| Q3 2024 Q2Q % growth | -1.01 28.37% | -1.45 | 0.44 | 30.41% |
| Q2 2024 Q2Q % growth | -1.49 -52.04% | -1.55 | 0.06 | 4.06% |
| Q1 2024 Q2Q % growth | -1.43 -113.43% | -1.36 | -0.07 | -5.19% |
| Q4 2023 Q2Q % growth | 1.10 178.01% | -0.07 | 1.17 | 1,593.05% |
| Q3 2023 Q2Q % growth | -1.41 37.05% | -1.99 | 0.58 | 29.13% |
| Q2 2023 Q2Q % growth | -0.98 59.17% | -2.16 | 1.18 | 54.63% |
| Q1 2023 Q2Q % growth | -0.67 71.12% | -1.74 | 1.07 | 61.43% |
| Q4 2022 Q2Q % growth | -1.41 23.37% | -2.35 | 0.94 | 39.87% |
| Q3 2022 Q2Q % growth | -2.24 -34.13% | -2.34 | 0.10 | 4.11% |
| Q2 2022 Q2Q % growth | -2.40 -125.42% | -2.27 | -0.13 | -5.64% |
| Q1 2022 Q2Q % growth | -2.32 -53.64% | -1.98 | -0.34 | -17.46% |
| Q4 2021 Q2Q % growth | -1.84 -22.67% | -1.80 | -0.04 | -1.98% |
| Q3 2021 Q2Q % growth | -1.67 -26.52% | -1.79 | 0.12 | 6.77% |
| Q2 2021 Q2Q % growth | 9.44 826.15% | 3.59 | 5.85 | 162.72% |
| Q1 2021 Q2Q % growth | -1.51 -31.30% | -1.50 | -0.01 | -0.53% |
| Q4 2020 Q2Q % growth | -1.50 -394.12% | -1.30 | -0.20 | -15.52% |
| Q3 2020 Q2Q % growth | -1.32 -155.00% | -1.21 | -0.11 | -9.22% |
| Q2 2020 Q2Q % growth | -1.30 -28.71% | -0.97 | -0.33 | -34.71% |
| Q1 2020 Q2Q % growth | -1.15 -23.66% | -1.07 | -0.08 | -7.34% |
| Q4 2019 Q2Q % growth | 0.51 | -0.64 | 1.15 | 179.88% |
| Q3 2019 Q2Q % growth | 2.40 | -0.97 | 3.37 | 348.11% |
| Q2 2019 Q2Q % growth | -1.01 | -0.92 | -0.09 | -10.27% |
| Q1 2019 Q2Q % growth | -0.93 | -0.90 | -0.03 | -3.20% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 35.691M -82.26% | 8.044M | 27.647M | 343.70% |
| Q3 2024 Q2Q % growth | 602K | 6.944M | -6.342M | -91.33% |
| Q2 2024 Q2Q % growth | 517K -99.26% | 3.609M | -3.092M | -85.67% |
| Q1 2024 Q2Q % growth | 504K -99.50% | 27.076M | -26.572M | -98.14% |
| Q4 2023 Q2Q % growth | 201.206M | 134.27M | 66.936M | 49.85% |
| Q3 2023 Q2Q % growth | -100.00% | 8.117M | -8.117M | -100.00% |
| Q2 2023 Q2Q % growth | 70M 34,900.00% | 1.742M | 68.258M | 3,918.37% |
| Q1 2023 Q2Q % growth | 100M 11,011.11% | 23.44M | 76.56M | 326.62% |
| Q4 2022 Q2Q % growth | -100.00% | 7.265M | -7.265M | -100.00% |
| Q3 2022 Q2Q % growth | 100K -87.50% | 1.649M | -1.549M | -93.94% |
| Q2 2022 Q2Q % growth | 200K -99.98% | 2.105M | -1.905M | -90.50% |
| Q1 2022 Q2Q % growth | 900K 80.00% | 2.82M | -1.92M | -68.09% |
| Q4 2021 Q2Q % growth | 12.9M 3,125.00% | 2.318M | 10.582M | 456.51% |
| Q3 2021 Q2Q % growth | 800K 700.00% | 1.145M | -345K | -30.13% |
| Q2 2021 Q2Q % growth | 900.7M | 429.34M | 471.36M | 109.79% |
| Q1 2021 Q2Q % growth | 500K 150.00% | 1.159M | -659K | -56.86% |
| Q4 2020 Q2Q % growth | 400K -99.48% | 2.372M | -1.972M | -83.14% |
| Q3 2020 Q2Q % growth | 100K -99.95% | 2.066M | -1.966M | -95.16% |
| Q2 2020 Q2Q % growth | -100.00% | 18.488M | -18.488M | -100.00% |
| Q1 2020 Q2Q % growth | 200K -33.33% | 3.103M | -2.903M | -93.55% |
| Q4 2019 Q2Q % growth | 77M | 36.543M | 40.457M | 110.71% |
| Q3 2019 Q2Q % growth | 211.9M | 6.279M | 205.621M | 3,274.74% |
| Q2 2019 Q2Q % growth | 300K | 4.016M | -3.716M | -92.53% |
| Q1 2019 Q2Q % growth | 300K | 1.785M | -1.485M | -83.19% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 6.71% | 1.61% | 2.38% | 3% |
| Revenue | -23.2% | -78.96% | -9.3% | -22.36% |